Literature DB >> 8641971

Characterization of transendothelial migratory lymphokine-activated killer cells.

K Nakano1, M Eura, K Chikamatsu, K Masuyama, T Ishikawa.   

Abstract

We examined the killing activity of transmigrated lymphokine-activated killer (LAK) cells and their surface molecules associated with both transendothelial migration and cytotoxicity, using human umbilical vein-derived endothelial cell (HUVEC) monolayers on fibronectin with gelatin separating the upper chamber from the lower chamber. Migratory LAK cells were significantly more cytotoxic to Daudi target cells, expressed more LFA-1, and were more likely to be positive for CD2, compared to those LAK cells not adherent to the HUVEC monolayer. In contrast, in the absence of the HUVEC monolayer, there was no difference in LAK activity between migratory and non-adherent LAK cells. These results indicate that the interaction between LAK cells and the HUVEC monolayer allows selective migration of LAK cells with cytotoxic activity that is enhanced with respect to some surface molecules.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8641971      PMCID: PMC5921104          DOI: 10.1111/j.1349-7006.1996.tb00235.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  27 in total

1.  Adoptive immunotherapy for head and neck cancer with killer cells induced by stimulation with autologous or allogeneic tumour cells and recombinant interleukin-2.

Authors:  T Ishikawa; T Ikawa; M Eura; T Fukiage; K Masuyama
Journal:  Acta Otolaryngol       Date:  1989 May-Jun       Impact factor: 1.494

2.  In vivo migration and tissue localization of highly purified lymphokine-activated killer cells (A-LAK cells) in tumor-bearing rats.

Authors:  R E Felgar; J C Hiserodt
Journal:  Cell Immunol       Date:  1990-09       Impact factor: 4.868

3.  Role of CD11/CD18 in adhesion and transendothelial migration of T cells. Analysis utilizing CD18-deficient T cell clones.

Authors:  A F Kavanaugh; E Lightfoot; P E Lipsky; N Oppenheimer-Marks
Journal:  J Immunol       Date:  1991-06-15       Impact factor: 5.422

4.  In vivo distribution of recombinant interleukin-2-activated autologous lymphocytes administered by intra-arterial infusion in patients with renal cell carcinoma.

Authors:  T Morita; Y Yonese; N Minato
Journal:  J Natl Cancer Inst       Date:  1987-03       Impact factor: 13.506

5.  Tumor-derived transforming growth factor-beta 1 and interleukin-6 are chemotactic for lymphokine-activated killer cells.

Authors:  N Delens; E Torreele; H Savelkool; P De Baetselier; L Bouwens
Journal:  Int J Cancer       Date:  1994-06-01       Impact factor: 7.396

6.  Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria.

Authors:  E A Jaffe; R L Nachman; C G Becker; C R Minick
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

7.  T11/CD2 activation of cloned human natural killer cells results in increased conjugate formation and exocytosis of cytolytic granules.

Authors:  R E Schmidt; J P Caulfield; J Michon; A Hein; M M Kamada; R P MacDermott; R L Stevens; J Ritz
Journal:  J Immunol       Date:  1988-02-01       Impact factor: 5.422

8.  Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.

Authors:  S L Topalian; D Solomon; F P Avis; A E Chang; D L Freerksen; W M Linehan; M T Lotze; C N Robertson; C A Seipp; P Simon
Journal:  J Clin Oncol       Date:  1988-05       Impact factor: 44.544

9.  Eosinophil transendothelial migration induced by cytokines. III. Effect of the chemokine RANTES.

Authors:  M Ebisawa; T Yamada; C Bickel; D Klunk; R P Schleimer
Journal:  J Immunol       Date:  1994-09-01       Impact factor: 5.422

10.  Human T lymphocyte adhesion to endothelial cells and transendothelial migration. Alteration of receptor use relates to the activation status of both the T cell and the endothelial cell.

Authors:  N Oppenheimer-Marks; L S Davis; P E Lipsky
Journal:  J Immunol       Date:  1990-07-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.